Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848
Stephen Delaney, Mark Biffen, Justine Maltby, John Bell, Sara Asimus, Ajay Aggarwal, Maarten Kraan, David Keeling, Stephen Delaney, Mark Biffen, Justine Maltby, John Bell, Sara Asimus, Ajay Aggarwal, Maarten Kraan, David Keeling
Abstract
Background: Many patients with asthma have a T-helper type 2 (Th2) driven inflammation of the lung, whereas toll-like receptor 7 (TLR7) agonists, by inducing type I interferons, inhibit Th2 responses. In man, oral or parenteral TLR7 agonists can induce influenza-like symptoms through systemic induction of type I interferons. Design of a TLR7 agonist that is only active in the lung could reduce the risk of side effects and offer a new means for treating asthma. We developed a TLR7 agonist antedrug, AZD8848, to determine its local and systemic effects in preclinical models and man.
Methods: In vitro cellular potencies for the TLR7 antedrug agonist, AZD8848, were determined along with pharmacokinetics and efficacy in a rat allergy model. Sputum and blood biomarkers were measured in single ascending and multiple ascending dose clinical studies following inhalation delivery of AZD8848 and tolerability assessed.
Results: AZD8848 was potent in cellular assays and pharmacokinetics confirmed lack of systemic exposure to AZD8848. Weekly lung dosing in an animal model showed efficacy 26 days beyond the final dose. In healthy volunteers, AZD8848 was initially well tolerated with target engagement being demonstrated by induction of CXCL10 in sputum. A second inhaled dose, given 1 week later, amplified the systemic interferon signal in more than half the participants and resulted in significant influenza-like symptoms.
Conclusions: The antedrug design restricted the direct actions of AZD8848 to the lung. However, the type I interferon induced locally by TLR7 spilled over systemically, limiting the utility of this inhaled antedrug approach.
Trial registration number: NCT01560234, NCT01818869.
Keywords: Allergic lung disease; Asthma; Asthma Mechanisms.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4769423/bin/bmjresp2015000113f01.jpg)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4769423/bin/bmjresp2015000113f02.jpg)
Figure 3
Pharmacokinetics and biomarker induction following…
Figure 3
Pharmacokinetics and biomarker induction following a single inhaled dose of AZD8848 in man.(A)…
Figure 4
Plasma CXCL10 and blood lymphocyte…
Figure 4
Plasma CXCL10 and blood lymphocyte counts following a second inhaled dose of AZD8848.…
Figure 5
Monitoring the induction of pro-inflammatory…
Figure 5
Monitoring the induction of pro-inflammatory mediators and toll-like receptors (TLRs) following inhalation of…
- Temporal cytokine and lymphoid responses to an inhaled TLR7 antedrug agonist in the cynomolgus monkey demonstrates potential safety and tolerability of this approach.Bell J, Dymond M, Biffen M, Delaney S, Keeling D, Zhang H, Robinson I. Bell J, et al. Toxicol Appl Pharmacol. 2018 Jan 1;338:9-19. doi: 10.1016/j.taap.2017.11.002. Epub 2017 Nov 6. Toxicol Appl Pharmacol. 2018. PMID: 29122671
- Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study.Leaker BR, Singh D, Lindgren S, Almqvist G, Eriksson L, Young B, O'Connor B. Leaker BR, et al. Respir Res. 2019 Dec 19;20(1):288. doi: 10.1186/s12931-019-1252-2. Respir Res. 2019. PMID: 31856838 Free PMC article. Clinical Trial.
- Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis.Greiff L, Cervin A, Ahlström-Emanuelsson C, Almqvist G, Andersson M, Dolata J, Eriksson L, Högestätt E, Källén A, Norlén P, Sjölin IL, Widegren H. Greiff L, et al. Respir Res. 2012 Jun 22;13(1):53. doi: 10.1186/1465-9921-13-53. Respir Res. 2012. PMID: 22726593 Free PMC article. Clinical Trial.
- A new era of targeting the ancient gatekeepers of the immune system: toll-like agonists in the treatment of allergic rhinitis and asthma.Aryan Z, Holgate ST, Radzioch D, Rezaei N. Aryan Z, et al. Int Arch Allergy Immunol. 2014;164(1):46-63. doi: 10.1159/000362553. Epub 2014 May 21. Int Arch Allergy Immunol. 2014. PMID: 24853609 Review.
- Toll-Like Receptor 7-Targeted Therapy in Respiratory Disease.Lebold KM, Jacoby DB, Drake MG. Lebold KM, et al. Transfus Med Hemother. 2016 Mar;43(2):114-9. doi: 10.1159/000445324. Epub 2016 Mar 22. Transfus Med Hemother. 2016. PMID: 27226793 Free PMC article. Review.
- Bacterial vesicles block viral replication in macrophages via TLR4-TRIF-axis.Bierwagen J, Wiegand M, Laakmann K, Danov O, Limburg H, Herbel SM, Heimerl T, Dorna J, Jonigk D, Preußer C, Bertrams W, Braun A, Sewald K, Schulte LN, Bauer S, Pogge von Strandmann E, Böttcher-Friebertshäuser E, Schmeck B, Jung AL. Bierwagen J, et al. Cell Commun Signal. 2023 Mar 28;21(1):65. doi: 10.1186/s12964-023-01086-4. Cell Commun Signal. 2023. PMID: 36978183 Free PMC article.
- Advancing Adjuvants for Mycobacterium tuberculosis Therapeutics.Enriquez AB, Izzo A, Miller SM, Stewart EL, Mahon RN, Frank DJ, Evans JT, Rengarajan J, Triccas JA. Enriquez AB, et al. Front Immunol. 2021 Oct 25;12:740117. doi: 10.3389/fimmu.2021.740117. eCollection 2021. Front Immunol. 2021. PMID: 34759923 Free PMC article. Review.
- TLR2-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs.Deliyannis G, Wong CY, McQuilten HA, Bachem A, Clarke M, Jia X, Horrocks K, Zeng W, Girkin J, Scott NE, Londrigan SL, Reading PC, Bartlett NW, Kedzierska K, Brown LE, Mercuri F, Demaison C, Jackson DC, Chua BY. Deliyannis G, et al. JCI Insight. 2021 Mar 8;6(5):e140267. doi: 10.1172/jci.insight.140267. JCI Insight. 2021. PMID: 33561017 Free PMC article.
- Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy.Kirtland ME, Tsitoura DC, Durham SR, Shamji MH. Kirtland ME, et al. Front Immunol. 2020 Nov 12;11:599083. doi: 10.3389/fimmu.2020.599083. eCollection 2020. Front Immunol. 2020. PMID: 33281825 Free PMC article. Review.
- EAACI Allergen Immunotherapy User's Guide.Alvaro-Lozano M, Akdis CA, Akdis M, Alviani C, Angier E, Arasi S, Arzt-Gradwohl L, Barber D, Bazire R, Cavkaytar O, Comberiati P, Dramburg S, Durham SR, Eifan AO, Forchert L, Halken S, Kirtland M, Kucuksezer UC, Layhadi JA, Matricardi PM, Muraro A, Ozdemir C, Pajno GB, Pfaar O, Potapova E, Riggioni C, Roberts G, Rodríguez Del Río P, Shamji MH, Sturm GJ, Vazquez-Ortiz M. Alvaro-Lozano M, et al. Pediatr Allergy Immunol. 2020 May;31 Suppl 25(Suppl 25):1-101. doi: 10.1111/pai.13189. Pediatr Allergy Immunol. 2020. PMID: 32436290 Free PMC article. Review.
-
- Pearce N, Ait-Khaled N, Beasley R et al. . Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2007;62:758–66. doi:10.1136/thx.2006.070169 - DOI - PMC - PubMed
-
- Pawankar R. Allergic diseases and asthma: a global public health concern and a call to action. World Allergy Organ J 2014;7:12 doi:10.1186/1939-4551-7-12 - DOI - PMC - PubMed
-
- Braun-Fahrlander C, Riedler J, Herz U et al. . Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 2002;347:869–77. doi:10.1056/NEJMoa020057 - DOI - PubMed
-
- Gern JE. Barnyard microbes and childhood asthma. N Engl J Med 2011;364:769–70. doi:10.1056/NEJMe1013713 - DOI - PubMed
-
- Romagnani S. The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology 2004;112:352–63. doi:10.1111/j.1365-2567.2004.01925.x - DOI - PMC - PubMed
- ClinicalTrials.gov/NCT01560234
- ClinicalTrials.gov/NCT01818869
- Full Text Sources
- Other Literature Sources
- Medical
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4769423/bin/bmjresp2015000113f03.jpg)
Figure 4
Plasma CXCL10 and blood lymphocyte…
Figure 4
Plasma CXCL10 and blood lymphocyte counts following a second inhaled dose of AZD8848.…
Figure 5
Monitoring the induction of pro-inflammatory…
Figure 5
Monitoring the induction of pro-inflammatory mediators and toll-like receptors (TLRs) following inhalation of…
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4769423/bin/bmjresp2015000113f04.jpg)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4769423/bin/bmjresp2015000113f05.jpg)
References
- Pearce N, Ait-Khaled N, Beasley R et al. . Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2007;62:758–66.
- Pawankar R. Allergic diseases and asthma: a global public health concern and a call to action. World Allergy Organ J 2014;7:12
- Braun-Fahrlander C, Riedler J, Herz U et al. . Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 2002;347:869–77.
- Gern JE. Barnyard microbes and childhood asthma. N Engl J Med 2011;364:769–70.
- Romagnani S. The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology 2004;112:352–63.
- Holgate ST. Pathogenesis of asthma. Clin Exp Allergy 2008;38:872–97.
- Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010;327:291–5.
- Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335–76.
- Camateros P, Tamaoka M, Hassan M et al. . Chronic asthma-induced airway remodeling is prevented by toll-like receptor-7/8 ligand S28463. Am J Respir Crit Care Med 2007;175:1241–9.
- Vultaggio A, Nencini F, Fitch PM et al. . Modified adenine (9-benzyl-2-butoxy-8-hydroxyadenine) redirects Th2-mediated murine lung inflammation by triggering TLR7. J Immunol 2009;182:880–9.
- Xirakia C, Koltsida O, Stavropoulos A et al. . Toll-like receptor 7-triggered immune response in the lung mediates acute and long-lasting suppression of experimental asthma. Am J Respir Crit Care Med 2010;181:1207–16.
- Grela F, Aumeunier A, Bardel E et al. . The TLR7 agonist R848 alleviates allergic inflammation by targeting invariant NKT cells to produce IFN-gamma. J Immunol 2011;186:284–90.
- Moisan J, Camateros P, Thuraisingam T et al. . TLR7 ligand prevents allergen-induced airway hyperresponsiveness and eosinophilia in allergic asthma by a MYD88-dependent and MK2-independent pathway. Am J Physiol Lung Cell Mol Physiol 2006;290: L987–95.
- Sel S, Wegmann M, Sel S et al. . Immunomodulatory effects of viral TLR ligands on experimental asthma depend on the additive effects of IL-12 and IL-10. J Immunol 2007;178:7805–13.
- Edwards S, Jones C, Leishman AJ et al. . TLR7 stimulation of APCs results in inhibition of IL-5 through type I IFN and Notch signaling pathways in human peripheral blood mononuclear cells. J Immunol 2013;190:2585–92.
- Matsui H, Tomizawa H, Eiho K et al. . Mechanism of action of inhibition of allergic immune responses by a novel antedrug TLR7 agonist. J Immunol 2012;189:5194–205.
- Campbell JD, Kell SA, Kozy HM et al. . A limited CpG-containing oligodeoxynucleotide therapy regimen induces sustained suppression of allergic airway inflammation in mice. Thorax 2014;69:565–73.
- Biffen M, Matsui H, Edwards SE et al. . Biological characterisation of a novel class of toll-like receptor 7 (TLR7) agonists designed to have reduced systemic activity. Br J Pharmacol 2012;166:573–86.
- Huber JP, Ramos HJ, Gill MA et al. . Cutting edge: type I IFN reverses human Th2 commitment and stability by suppressing GATA3. J Immunol 2010;185:813–17.
- Fidock MD, Souberbielle BE, Laxton C et al. . The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther 2011;89:821–9.
- Dudek AZ, Yunis C, Harrison LI et al. . First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res 2007;13:7119–25.
- Pockros PJ, Guyader D, Patton H et al. . Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol 2007;47:174–82.
- Kurimoto A, Hashimoto K, Nakamura T et al. . Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept. J Med Chem 2010;53:2964–72.
- Greiff L, Cervin A, Ahlstrom-Emanuelsson C et al. . Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res 2012;13:53
- Pavord ID, Pizzichini MMM, Pizzichini E et al. . The use of induced sputum to investigate airway inflammation. Thorax 1997;52:498–501.
- Padovan E, Spagnoli GC, Ferrantini M et al. . IFN-(alpha)2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+effector T cells. J Leukoc Biol 2002;71:669–76.
- Tovey MG, Lallemand C. Safety, tolerability, and immunogenicity of interferons. Pharmaceuticals 2010;3:1162–86.
- Kamphuis E, Junt T, Waibler Z et al. . Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 2006;108:3253–61.
- Koga-Yamakawa E, Murata M, Dovedi SJ et al. . TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice. Cancer Immunol Immunother 2015;64:1229–39.
Source: PubMed